Clinical Trial

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the…

1 year ago

Loftware and Signant Health Announce Availability of Integrated Clinical Supplies Labeling Solution

Automates to improve speed, enable compliance, and support scalability PORTSMOUTH, N.H., Oct. 31, 2024 /PRNewswire/ -- Loftware, the global leader…

1 year ago

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today…

1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative…

1 year ago

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Conference call and webcast to begin at 8:30 AM ETAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.…

1 year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit…

1 year ago

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

1 year ago

Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer

Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,…

1 year ago

Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer

Accomplished Finance and Commercial Leader Brings Extensive Life Sciences ExpertiseCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc.…

1 year ago